Publication | Closed Access
Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
30
Citations
7
References
1993
Year
Edatrexate is an active agent against metastatic breast cancer, with acceptable toxicity. A lower than planned delivered dose-intensity was mainly due to mucositis.
| Year | Citations | |
|---|---|---|
Page 1
Page 1